6 completed, 2 recruiting. 5 Phase 4, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 4, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Peter Rossing: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease Dapagliflozin, Semaglutide, Finerenone - Chronic Kidney Disease(CKD) | Phase 4 | Recruiting | Peter Rossing | 125 | 2025-06-20 | 2025-11-20 |
| Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study Kerendia (Finerenone, BAY94-8862), Placebo - Cardiovascular Autonomic Neuropathy, Type 2 Diabetes | Phase 2 | Recruiting | Peter Rossing | 100 | 2025-05-02 | 2025-05-25 |
| PeRsOnalising Treatment Of Diabetic Nephropathy: Diabetes Mellitus, Type 1, Diabetes Complications | Completed | Peter Rossing | 210 | 2016-04-01 | 2018-04-26 | |
| Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes Dapagliflozine 10 mg once daily tablet treatment, Placebo identical once daily tablet treatment - Type 2 Diabetes, Diabetic Nephropathy | Phase 4 | Completed | Peter Rossing | 40 | 2015-08-01 | 2018-09-10 |
| Microalbuminuria and Allopurinol in Type 1 Diabetes Allopurinol, Placebo - Type 1 Diabetes, Diabetic Nephropathy | Phase 4 | Completed | Peter Rossing | 30 | 2014-09-01 | 2018-09-10 |
| Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria Spironolactone, Placebo, Standard care - Diabetic Nephropathy, Diabetic Retinopathy | Phase 2 / Phase 3 | Completed | Peter Rossing | 1777 | 2014-03-01 | 2018-12-21 |
| Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes liraglutide - Type 2 Diabetes | Phase 4 | Completed | Peter Rossing | 32 | 2012-08-01 | 2015-02-02 |
| Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy Paricalcitol - Cardiovascular Disease, Diabetic Nephropathy | Phase 4 | Completed | Peter Rossing | 48 | 2010-04-01 | 2012-04-13 |
Diabetic Nephropathies (5) · Diabetes Mellitus, Type 2 (3) · Albuminuria (2) · Diabetes Mellitus, Type 1 (2) · Renal Insufficiency, Chronic (2) · Cardiovascular Diseases (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Neuropathies (1) · Diabetic Retinopathy (1) · Hypertension (1)
finerenone (2) · Allopurinol (1) · Liraglutide (1) · Spironolactone (1) · Standard of Care (1) · dapagliflozin (1) · paricalcitol (1) · semaglutide (1)
Denmark (8) · Germany (2) · Spain (2) · Belgium (1) · Czechia (1) · Greece (1) · Italy (1) · Netherlands (1) · North Macedonia (1) · Sweden (1) · United Kingdom (1)
Adriaan Kooy, MD (1) · Alberto Ortiz, MD (1) · Andreas Birkenfeld, MD (1) · Christian Delles, MD (1) · Gerjan Navis, MD (1) · Goce Spasovski, MD (1) · Ivan Rychlik, MD (1) · Joachim Beige, MD (1) · Joline Beulens, MD (1) · Lise Tarnow, MD (1) · Marina Noutsou, MD (1) · Marjin Speeckaert, MD (1) · Matias Trillini, MD (1) · Peter Girman, MD (1)
PMID 25935863, PMID 26936907, PMID 29781558, PMID 32135136, PMID 32340841, PMID 33107592, PMID 35998283, PMID 36841085, PMID 37171199, PMID 38449081, PMID 39434255, PMID 41130701
2009 (1), 2015 (1), 2023 (1)